newsfilter
← Latest News
GlobeNewswire·

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose